Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H17FN8O2 |
Molecular Weight | 408.3891 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=NC=CC=C24
InChI
InChIKey=FTQHGWIXJSSWOY-UHFFFAOYSA-N
InChI=1S/C19H17FN8O2/c1-30-19(29)24-14-15(21)25-17(26-16(14)22)13-11-6-4-8-23-18(11)28(27-13)9-10-5-2-3-7-12(10)20/h2-8H,9H2,1H3,(H,24,29)(H4,21,22,25,26)
Molecular Formula | C19H17FN8O2 |
Molecular Weight | 408.3891 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Nelociguat, a soluble guanylate cyclase (sGC) activator, has been in phase II clinical trials by Bayer for the treatment of erectile dysfunction and heart failure. However, no recent development has been reported. Nelociguat is a direct soluble guanylate cyclase (sGC) stimulator that acts independently of nitric oxide (NO); has an EC50 of 353 nM on P-VASP formation in rat aortic smooth muscle cells. BAY 60-4552 is pharmacologically active major metabolite of Riociguat.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27784018 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00565565
Heart Failure: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.probechem.com/products_Nelociguat.aspx
Nelociguat has an EC50 of 353 nM on P-VASP formation in rat aortic smooth muscle cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:39:39 GMT 2023
by
admin
on
Fri Dec 15 20:39:39 GMT 2023
|
Record UNII |
M2A18LL56O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034301
Created by
admin on Fri Dec 15 20:39:39 GMT 2023 , Edited by admin on Fri Dec 15 20:39:39 GMT 2023
|
PRIMARY | |||
|
M2A18LL56O
Created by
admin on Fri Dec 15 20:39:39 GMT 2023 , Edited by admin on Fri Dec 15 20:39:39 GMT 2023
|
PRIMARY | |||
|
9477
Created by
admin on Fri Dec 15 20:39:39 GMT 2023 , Edited by admin on Fri Dec 15 20:39:39 GMT 2023
|
PRIMARY | |||
|
11690019
Created by
admin on Fri Dec 15 20:39:39 GMT 2023 , Edited by admin on Fri Dec 15 20:39:39 GMT 2023
|
PRIMARY | |||
|
149785
Created by
admin on Fri Dec 15 20:39:39 GMT 2023 , Edited by admin on Fri Dec 15 20:39:39 GMT 2023
|
PRIMARY | |||
|
625115-52-8
Created by
admin on Fri Dec 15 20:39:39 GMT 2023 , Edited by admin on Fri Dec 15 20:39:39 GMT 2023
|
PRIMARY | |||
|
C174685
Created by
admin on Fri Dec 15 20:39:39 GMT 2023 , Edited by admin on Fri Dec 15 20:39:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
The protein binding of M1 is ~97% and is concentration independent.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE LESS ACTIVE |
MAJOR
FECAL; PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||